Idera Pharma (IDRA) Reports In-Line Q2 Loss

Idera Pharma (NASDAQ: IDRA) reported Q2 EPS of ($0.11), in-line with the analyst estimate of ($0.11). Revenue for the quarter came in at $301 thousand versus the consensus estimate of $143 thousand.

For earnings history and earnings-related data on Idera Pharma (IDRA) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Yeti Holdings Inc. (YETI) PT Raised to $45 at Stifel on Beat and Raise Q2 Results